Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2015

View Archived Issues

New 3D cell culture model provides data validation for amyloid hypothesis

New compounds assessed as potential PET tracers for AD and other tauopathies

Rotary releases funding to support polio efforts

Merck KGaA details novel inhibitors for cancer among other diseases

Lupin patent divulges novel IL-2 inhibitors

FDA awards fast track designation to Celator's CPX-351 for acute myeloid leukemia

MorphoSys describes ongoing pipeline

First-in-human results show efficacy of a novel PET tau tracer

Enanta presents pipeline outlook

Palbociclib is well tolerated in patients with advanced HCC

Phase I/II results of isactuzumab govitecan in gastrointestinal cancer patients

Scientists at Emory University patent novel NMDA receptor antagonists

Piramal Enterprises researchers prepare new insulin sensitizers

Investigators in Portugal disclose novel TP53 activators for cancer

UCB confirms regulatory filings for antiepileptic drug brivaracetam

New Abeta inhibitors designed by investigators in France

Companies patent new SMN2 expression enhancers for spinal muscular atrophy

Spiriva Respimat inhalation spray now available in the U.S.

Zymeworks forms bispecific antibody collaboration with Celgene

Tekmira initiates phase I clinical trial of TKM-HBV

Curis and Aurigene to develop small-molecule antagonists for oncology targets

Ventana seeks FDA premarket approval for ALK companion diagnostic for lung cancer

FDA approves Cosentyx for moderate to severe plaque psoriasis

European Commission approves Cerdelga for type 1 Gaucher's disease

FDA grants orphan drug status to cell-based gene therapy

Sanguinate receives FDA orphan drug status for SCD comorbidities

VolitionRx begins feasibility study for NuQ assay in ovarian cancer

EMA accepts AstraZeneca's lesinurad MAA for gout

Minerva Neurosciences reports phase I data for orexin OX2 receptor antagonist MIN-202